CClinicalTrials.gg
Not yet recruitingNCT07770906GLP1-PERIOUpdated Aug 20, 2026

Effect of GLP-1 Receptor Agonists on Periodontal Health and Response to Nonsurgical Periodontal Therapy

An interventional study of non-surgical periodontal therapy in Periodontal Disease and Obesity & Overweight, sponsored by Cukurova University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Cukurova University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Sex
All
01

Study summary

This study aims to evaluate the effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use on periodontal health and the response to non-surgical periodontal therapy in individuals with obesity and periodontitis.

Participants with obesity and periodontitis will be divided into two groups: those who have been using a GLP-1 RA for at least 3 months and those who are not using any medication for obesity. All participants will receive the same non-surgical periodontal treatment, including oral hygiene instruction, scaling, and root planing.

Periodontal clinical measurements and gingival crevicular fluid samples will be collected before treatment and at 3 and 6 months after treatment. The study will compare changes in periodontal health and inflammatory markers between the two groups to determine whether GLP-1 RA use is associated with periodontal health and the response to non-surgical periodontal therapy.

Read the detailed description

This prospective, controlled clinical study aims to compare periodontal clinical parameters and gingival crevicular fluid inflammatory markers between individuals with obesity and periodontitis who use GLP-1 RAs and those who do not use pharmacological treatment for obesity. The study will also evaluate and compare the clinical response to non-surgical periodontal therapy between the two groups.

A total of 40 participants with obesity and periodontitis will be included and allocated to two groups. The GLP-1 RA group will consist of 20 participants who have been regularly using a GLP-1 RA (semaglutide, liraglutide, or dulaglutide) for at least 3 months because of obesity. The control group will consist of 20 participants with obesity and periodontitis who are not using any medication for obesity.

All participants will receive the same non-surgical periodontal treatment protocol. Following the baseline periodontal examination, participants will receive oral hygiene instructions, including instruction in the modified Bass toothbrushing technique. Non-surgical periodontal therapy will be completed in two sessions under local anesthesia and will include full-mouth subgingival instrumentation and scaling and root planing using ultrasonic instruments and Gracey curettes. No adjunctive antimicrobial agents will be used. Participants in the GLP-1 RA group will continue their existing systemic GLP-1 RA treatment without modification.

Periodontal clinical assessments will include probing depth, clinical attachment level, bleeding on probing, plaque index, and gingival index. Gingival crevicular fluid samples will be collected using sterile PerioPaper® strips and stored at -80°C until analysis. Body mass index, HbA1c, and fasting blood glucose will also be evaluated using the measurements and laboratory results specified in the study protocol.

Clinical periodontal measurements and gingival crevicular fluid sampling will be performed at baseline and repeated at 3 and 6 months following non-surgical periodontal therapy. During follow-up visits, oral hygiene instructions will be reinforced, and professional supragingival cleaning will be performed when supragingival calculus accumulation is detected.

Changes in periodontal clinical parameters and gingival crevicular fluid inflammatory markers will be compared between the GLP-1 RA and control groups. The study is designed to determine whether GLP-1 RA use is associated with differences in periodontal inflammatory status and clinical response to non-surgical periodontal therapy in individuals with obesity and periodontitis.

02

Conditions studied

  • Periodontal Disease
  • Obesity & Overweight

Keywords

  • PERIODONTAL DISEASE
  • OBESİTY
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age between 18 and 65 years
  • Body mass index (BMI) ≥25 kg/m²
  • Presence of at least 20 functional teeth
  • Diagnosis of periodontitis
  • For the GLP-1 receptor agonist group: regular use of a GLP-1 receptor agonist for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Age between 18 and 65 years
  • Body mass index (BMI) ≥25 kg/m²
  • Presence of at least 20 functional teeth
  • Diagnosis of periodontitis
  • For the GLP-1 receptor agonist group: regular use of a GLP-1 receptor agonist for at least 3 months
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Title: GLP-1 Receptor Agonist Group

    Procedure: non-surgical periodontal therapy

  • Placebo comparator
    Control Group

    Procedure: non-surgical periodontal therapy

Interventions

  • Procedurenon-surgical periodontal therapy

    All participants will receive oral hygiene instructions, including instruction in the modified Bass toothbrushing technique. Non-surgical periodontal therapy will be performed under local anesthesia in two sessions and will include full-mouth subgingival instrumentation and scaling and root planing using ultrasonic instruments and Gracey curettes. No adjunctive antimicrobial agents will be used.

05

What researchers measure

Primary outcomes

  1. Probing Depth

    Time frame: Baseline, 3 months- 6 months

Secondary outcomes

  1. Gingival Index

    Time frame: Baseline, 3months- 6 months

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07770906
Lead sponsor
Cukurova University
Responsible party
BAHAR ALKAYA (ASSOCIATE PROFESSOR, Cukurova University) — Principal investigator
First posted
Aug 18, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

bahar alkaya
Contact
balkaya@cu.edu.tr
+05368720327

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion